Phase 2 studies of the BR55 ultrasound contrast agent reportedly demonstrated a 95 percent accuracy in showing the expression of vascular endothelial growth factor receptor 2 (VEGFR2) in bowel segments reflecting active inflammation in patients with Crohn’s disease.
The Food and Drug Administration (FDA) has granted fast track designation to BR55, an emerging molecular ultrasound contrast agent, for the diagnosis of active bowel inflammation in patients with Crohn’s disease.
Targeting the vascular endothelial growth factor receptor 2 (VEGFR2), the injection of BR55 (perfluorobutane/nitrogen lipopeptide-coated microbubbles) achieved a 95 percent accuracy in revealing active bowel inflammation in patients with Crohn’s disease in phase 2 studies, according to Bracco Imaging, the developer of the ultrasound contrast agent.
The company maintained that the use of BR55 to detect angiogenesis through non-invasive, radiation-free ultrasound imaging may enhance monitoring and facilitate timely treatment in this patient population.
“The FDA fast track process is aimed at improving the management of patients with serious conditions and filling an unmet medical need, such as the accurate monitoring of disease activity in patients with Crohn's disease,” noted Alberto Spinazzi, M.D., the chief medical and regulatory officer for the Bracco Imaging Group. “This fast track designation supports our goal to get BR55 to the patient earlier and more efficiently."
Bracco Imaging noted that the efficacy and safety of BR55 will be evaluated in forthcoming multicenter, multinational phase 3 studies.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).